<SEC-DOCUMENT>0001474506-25-000108.txt : 20250611
<SEC-HEADER>0001474506-25-000108.hdr.sgml : 20250611
<ACCEPTANCE-DATETIME>20250611161152
ACCESSION NUMBER:		0001474506-25-000108
CONFORMED SUBMISSION TYPE:	3/A
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20250304
FILED AS OF DATE:		20250611
DATE AS OF CHANGE:		20250611

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Inscobee Inc.
		CENTRAL INDEX KEY:			0002057997
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		3/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42545
		FILM NUMBER:		251040125

	BUSINESS ADDRESS:	
		STREET 1:		ROOM 613, DIGITAL-RO 130, 6F
		STREET 2:		GEUMCHEON-GU
		CITY:			SEOUL
		STATE:			M5
		ZIP:			08580
		BUSINESS PHONE:		82-70-7600-7007

	MAIL ADDRESS:	
		STREET 1:		ROOM 613, DIGITAL-RO 130, 6F
		STREET 2:		GEUMCHEON-GU
		CITY:			SEOUL
		STATE:			M5
		ZIP:			08580

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apimeds Pharmaceuticals US, Inc.
		CENTRAL INDEX KEY:			0001894525
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				851099700
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		2 EAST BROAD STREET
		STREET 2:		2ND FLOOR
		CITY:			HOPEWELL
		STATE:			NJ
		ZIP:			08525
		BUSINESS PHONE:		848-201-5010

	MAIL ADDRESS:	
		STREET 1:		2 EAST BROAD STREET
		STREET 2:		2ND FLOOR
		CITY:			HOPEWELL
		STATE:			NJ
		ZIP:			08525
</SEC-HEADER>
<DOCUMENT>
<TYPE>3/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<DESCRIPTION>PRIMARY DOCUMENT
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3/A</documentType>

    <periodOfReport>2025-03-04</periodOfReport>

    <dateOfOriginalSubmission>2025-05-08</dateOfOriginalSubmission>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001894525</issuerCik>
        <issuerName>Apimeds Pharmaceuticals US, Inc.</issuerName>
        <issuerTradingSymbol>APUS</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0002057997</rptOwnerCik>
            <rptOwnerName>Inscobee Inc.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>ROOM 613, DIGITAL-RO 130, 6F</rptOwnerStreet1>
            <rptOwnerStreet2>GEUMCHEON-GU</rptOwnerStreet2>
            <rptOwnerCity>SEOUL</rptOwnerCity>
            <rptOwnerState>M5</rptOwnerState>
            <rptOwnerZipCode>08580</rptOwnerZipCode>
            <rptOwnerStateDescription>KOREA, REPUBLIC OF</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock, par value $0.01 per share</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>1484616</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock, par value $0.01 per share</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>4134616</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                    <footnoteId id="F1"/>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>By Apimeds Inc.</value>
                    <footnoteId id="F1"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Convertible Promissory Note</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>2.6</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F2"/>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F2"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock, par value $0.01 per share</value>
                </underlyingSecurityTitle>
                <underlyingSecurityValue>
                    <value>473205</value>
                    <footnoteId id="F2"/>
                </underlyingSecurityValue>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                    <footnoteId id="F1"/>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>By Apimeds Inc.</value>
                    <footnoteId id="F1"/>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Convertible Promissory Note</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>2.6</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F3"/>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F3"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock, par value $0.01 per share</value>
                </underlyingSecurityTitle>
                <underlyingSecurityValue>
                    <value>184833</value>
                    <footnoteId id="F3"/>
                </underlyingSecurityValue>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Convertible Promissory Note</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>2.6</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F4"/>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F4"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock, par value $0.01 per share</value>
                </underlyingSecurityTitle>
                <underlyingSecurityValue>
                    <value>114507</value>
                    <footnoteId id="F4"/>
                </underlyingSecurityValue>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The shares of common stock are owned directly by Apimeds Inc. (&quot;Apimeds Korea&quot;), which is a wholly owned subsidiary of the reporting person. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.</footnote>
        <footnote id="F2">On August 30, 2021, Apimeds Pharmaceuticals US, Inc. (the &quot;Issuer&quot;) issued to Apimeds Korea a convertible promissory note in the principal amount of $400,000 (as amended, the &quot;August 2021 Note&quot;). All outstanding principal and accrued and unpaid interest owed under the August 2021 Note is due and payable on the earlier of (i) December 31, 2026, or (ii) the consummation of an offering of the Issuer's common stock resulting in the listing of the Issuer's common stock on the NYSE American, or other national securities exchange (a &quot;Qualified Offering&quot;). The August 2021 Note bears interest at an annual rate of 5%. The August 2021 Note is convertible into shares of common stock at a conversion price of $2.60 per share (the &quot;Conversion Price&quot;). The amount reported in Column 3 of Table II represents the original principal amount of $400,000, plus $73,205 of accrued and unpaid interest.</footnote>
        <footnote id="F3">On March 21, 2022, the Issuer issued to Inscobee Inc. (&quot;Inscobee&quot;) a convertible promissory note in the principal amount of $160,000 (as amended, the &quot;March 2022 Note&quot;). All outstanding principal and accrued and unpaid interest owed under the March 2022 Note is due and payable on the earlier of (i) December 31, 2026, or (ii) the consummation of a Qualified Offering. The March 2022 Note bears interest at an annual rate of 5%. The March 2022 Note is convertible into shares of common stock at the Conversion Price. The amount reported in Column 3 of Table II represents the original principal amount of $160,000, plus $24,833 of accrued and unpaid interest.</footnote>
        <footnote id="F4">On June 3, 2022, the Issuer issued to Inscobee a convertible promissory note in the principal amount of $100,000 (as amended, the &quot;June 2022 Note&quot;). All outstanding principal and accrued and unpaid interest owed under the June 2022 Note is due and payable on the earlier of (i) December 31, 2026, or (ii) the consummation of a Qualified Offering. The June 2022 Note bears interest at an annual rate of 5%. The June 2022 Note is convertible into shares of common stock at the Conversion Price. The amount reported in Column 3 of Table II represents the original principal amount of $100,000, plus $14,507 of accrued and unpaid interest.</footnote>
    </footnotes>

    <remarks>On May 8, 2025, the reporting person filed a Form 3, which was subsequently amended on May 14, 2025, which incorrectly reported that the reporting person had indirect beneficial ownership of the Convertible Promissory Note in the amount of $184,833 (the &quot;Note&quot;) through Apimeds Korea. In fact, as reported in this amendment, the reporting person directly owned the Note.</remarks>

    <ownerSignature>
        <signatureName>/s/ Nelson Mullins Riley &amp; Scarborough LLP, Attorney-in-Fact</signatureName>
        <signatureDate>2025-06-11</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
